Literature DB >> 31344451

Predictors for Autoimmune Cytopenias after Allogeneic Hematopoietic Cell Transplantation in Children.

Celina L Szanto1, Jurgen Langenhorst1, Coco de Koning1, Stefan Nierkens2, Marc Bierings3, Alwin D R Huitema4, Caroline A Lindemans5, Jaap J Boelens6.   

Abstract

Development of autoimmune cytopenia (AIC) after allogeneic hematopoietic cell transplantation (HCT) is a serious complication requiring urgent intensification of immunosuppressive therapy. The pathophysiology and predictors of AIC are not completely understood. In this retrospective cohort analysis of 380 pediatric patients, we evaluated the incidence, outcomes, and related various variables, including immune reconstitution markers to AIC. Three hundred eighty patients (median age, 7.4 years; range, .1 to 22.7) were included, of which 30 patients (7.8%) developed AIC in 1 (n = 6), 2 (n = 6), or 3 (n = 16) cell lineages at a median of 133 days (range, 46 to 445) after HCT. Using multivariate analysis we found that chemo-naivety before HCT, acute graft-versus-host disease (aGVHD) grades II to IV, and serotherapy were associated with the development of AIC. Development of AIC was preceded by increased levels of IgM, IgA, and IgG. Immune profiles of total absolute lymphocytes were very similar between AIC patients and control subjects. However, CD3-CD16+CD56+ natural killer cells, CD3+ T cells, CD3+CD4+ T cell subset, and CD3+CD8+ T cell subset were lower in AIC patients. Overall survival was good, at 83% (similar between AIC patients and control subjects). In conclusion, we identified chemo-naivety before HCT, preceding aGVHD grades II to IV, and serotherapy as predictors for development of AIC. Increasing levels of IgM, IgA, and IgG preceded AIC development. These data provide clues to further study the biology of AIC.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Autoimmune cytopenia; Autoimmune hemolytic anemia; Autoimmune neutropenia; Autoimmune thrombocytopenia; Graft-versus-host disease; Hematopoietic cell transplantation; Immune monitoring; Immunoglobulins; Plasma cells

Mesh:

Substances:

Year:  2019        PMID: 31344451     DOI: 10.1016/j.bbmt.2019.07.022

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  7 in total

Review 1.  Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs).

Authors:  Markus G Seidel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 2.  Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force.

Authors:  Geoffrey D E Cuvelier; Michelle Schoettler; Nataliya P Buxbaum; Iago Pinal-Fernandez; Marc Schmalzing; Jörg H W Distler; Olaf Penack; Bianca D Santomasso; Robert Zeiser; Klemens Angstwurm; Kelli P A MacDonald; W Taylor Kimberly; Naomi Taylor; Ervina Bilic; Bernhard Banas; Maike Buettner-Herold; Namita Sinha; Hildegard T Greinix; Joseph Pidala; Kirk R Schultz; Kirsten M Williams; Yoshihiro Inamoto; Corey Cutler; Linda M Griffith; Stephanie J Lee; Stefanie Sarantopoulos; Steven Z Pavletic; Daniel Wolff
Journal:  Transplant Cell Ther       Date:  2022-05-31

3.  Autoimmune Cytopenias Post Hematopoietic Stem Cell Transplantation in Pediatric Patients With Osteopetrosis and Other Nonmalignant Diseases.

Authors:  Ehud Even-Or; Yael Dinur Schejter; Adeeb NaserEddin; Irina Zaidman; Bella Shadur; Polina Stepensky
Journal:  Front Immunol       Date:  2022-05-27       Impact factor: 8.786

4.  Characterizing Immune-Mediated Cytopenias After Allogeneic Hematopoietic Cell Transplantation for Pediatric Nonmalignant Disorders.

Authors:  Robert T Galvin; Qing Cao; Weston P Miller; Jessica Knight-Perry; Angela R Smith; Christen L Ebens
Journal:  Transplant Cell Ther       Date:  2021-01-20

Review 5.  Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.

Authors:  Ashish O Gupta; Jaap Jan Boelens; Christen L Ebens; Joanne Kurtzberg; Troy C Lund; Angela R Smith; John E Wagner; Robert Wynn; Bruce R Blazar; Paul J Orchard
Journal:  Bone Marrow Transplant       Date:  2021-01-13       Impact factor: 5.174

Review 6.  Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics.

Authors:  Yazan Migdady; Yifan Pang; Shelley S Kalsi; Richard Childs; Sally Arai
Journal:  Blood Adv       Date:  2022-04-26

7.  Autoimmune Cytopenias Developing Late Post Alemtuzumab-Based Allogeneic Stem Cell Transplantation: Presentation of Short Case Series from a Transplant Center.

Authors:  Rebecca Lloyd; Emmanouil Nikolousis; Bhuvan Kishore; Richard Lovell; Paneesha Shankara; Nervana Abou Zeid; Claire Horgan; Alkistis Kyra Panteliadou; Graham McIlroy; Evgenia Xenou; Maria Kaparou; Kathleen Holder; Vidhya Murthy; Alexandros Kanellopoulos
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.